Alnylam reveals RNAi therapeutics goals for 2013-14
RNAi specialist Alnylam Pharmaceuticals has outlined its research and development plans for the next 12 months.
Alnylam Pharmaceuticals, a leader in the field of RNA interference (RNAi) therapeutics, has revealed its main goals for the coming year.
Dr John Maraganore, the company's chief executive officer, revealed that the company made "tremendous" progress on its '5X15' pipeline in 2012.
This pipeline focuses on the development and commercialisation of novel RNAi therapeutics that address genetically defined diseases with a high degree of unmet medical need, such as haemophilia and severe hypercholesterolemia.
"The next couple of years promise to be transformative for Alnylam as we aim to advance our pipeline into phase-III, report on key clinical data in multiple programmes and expand the breadth of our '5x15' pipeline with additional clinical and pre-clinical programmes," Dr Maraganore revealed.
Giving further detail on the company's plans, he said that it is introducing a new development programme involving a product called ALN-AS1 for the treatment of an ultra-rare genetic disease called acute intermittent porphyria.
Dr Maraganore concluded that the company's ambitious goals for the coming year should help to advance innovative RNAi therapeutics and create value for its shareholders.
Barry Greene, Alnylam's president and chief operating officer, added that the company intends to directly sell its core '5x15' products in North and South America and Europe, while partnering to achieve market access in Japan and other Asian markets.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance